Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

QBQianming BaiXQXiaoqi Qin

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals autologous stem cell transplantation improves minimal residual disease in newly diagnosed multiple myeloma, indicating prognostic significance for progression-free.

Key Points

  • This research aims to analyze the dynamics of minimal residual disease and normal plasma cells following autologous stem cell transplantation.
  • Retrospective analysis of 400 patients with newly diagnosed multiple myeloma (NDMM) who received first-line high-dose therapy followed by ASCT.
  • Assessment of 1,351 MRD measurements and monitoring of normal plasma cells in bone marrow post-ASCT.
  • Evaluation of prognostic significance of MRD evolution and percentage of normal plasma cells (NPC%) in different groups.
  • ASCT significantly improved MRD status, with varied outcomes based on pre-transplant tumor burden and cytogenetic risk.
  • Patients sustaining MRD negativity after ASCT had longer progression-free survival compared to MRD-positive groups.
  • Normal plasma cell percentage was lower in MRD-positive patients, showing different recovery trajectories among MRD subgroups.

Cite This Study

Bai et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d073https://doi.org/10.1182/blood-2025-2241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2Detection of minimal residual disease after induction chemotherapy and autologous HSCT and its clinical significance in multiple myeloma2025
  3. 3Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  4. 4Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025
  5. 5Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents2025